Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

204 ARTÍCULOS , VIENDO DEL 46 AL 60

Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease

Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Tian ZR, Ozkizilcik A, Manzhulo I, Mössler H, Sharma A.

Prog Brain Res. 2019;245:145-200. doi: 10.1016/bs.pbr.2019.03.009. Epub 2019 Apr 2.

Extracellular Vesicle as a Source of Alzheimer's Biomarkers: Opportunities and Challenges

Lee S, Mankhong S, Kang JH.

Int J Mol Sci. 2019 Apr 8;20(7):1728. doi: 10.3390/ijms20071728.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker

Peña-Bautista C, Roca M, Hervás D, Cuevas A, López-Cuevas R, Vento M, Baquero M, García-Blanco A, Cháfer-Pericás C.

J Proteomics. 2019 May 30;200:144-152. doi: 10.1016/j.jprot.2019.04.008. Epub 2019 Apr 9.

Plasmalogens and Alzheimer's disease: a review

Su XQ, Wang J, Sinclair AJ.

Lipids Health Dis. 2019 Apr 16;18(1):100. doi: 10.1186/s12944-019-1044-1.

Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers

Farotti L, Sepe FN, Toja A, Rinaldi R, Parnetti L.

Clin Biochem. 2019 Oct;72:24-29. doi: 10.1016/j.clinbiochem.2019.04.011. Epub 2019 Apr 15.

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease

Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P.

Alzheimers Res Ther. 2019 Apr 22;11(1):34. doi: 10.1186/s13195-019-0485-0.

HIV and Alzheimer's disease: complex interactions of HIV-Tat with amyloid β peptide and Tau protein

Hategan A, Masliah E, Nath A.

J Neurovirol. 2019 Oct;25(5):648-660. doi: 10.1007/s13365-019-00736-z. Epub 2019 Apr 23.

Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis

Zhao Y, Xin Y, Meng S, He Z, Hu W.

Neurosci Biobehav Rev. 2019 Jul;102:123-138. doi: 10.1016/j.neubiorev.2019.04.014. Epub 2019 Apr 24.

Inflammatory biomarkers in Alzheimer's disease plasma

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium; Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease.

Alzheimers Dement. 2019 Jun;15(6):776-787. doi: 10.1016/j.jalz.2019.03.007. Epub 2019 Apr 30.

Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer's Disease

Jiang L, Dong H, Cao H, Ji X, Luan S, Liu J.

Med Sci Monit. 2019 May 6;25:3329-3335. doi: 10.12659/MSM.914027.

Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018

Vellas B, Bain LJ, Touchon J, Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):198-203. doi: 10.14283/jpad.2019.11.

Plasma Biomarkers: Potent Screeners of Alzheimer's Disease

Naveed M, Mubeen S, Khan A, Ibrahim S, Meer B.

Am J Alzheimers Dis Other Demen. 2019 Aug;34(5):290-301. doi: 10.1177/1533317519848239. Epub 2019 May 9.

Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers

Lee JC, Kim SJ, Hong S, Kim Y.

Exp Mol Med. 2019 May 9;51(5):1-10. doi: 10.1038/s12276-019-0250-2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias